A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants
N. Harrison, L. Richardson, C. Pallini, I. Morano, E. Jinks, J. Cowley, H. Chan, H. Hill, C. Matas de las Heras, A. Teodosio, A. S. Lavado, T. R. Dafforn, D. K. Grammatopoulos, J. Gordon, C. A. Brady, , O. S. Qureshi
The paper develops a cell-based ACE2/spike protein binding assay to assess antibody neutralising capacity against SARS-CoV-2 variants and shows differential blocking activity of monoclonal antibodies.
bioRxiv · Jun 24, 2022 · PreprintCell Biology